Loratadin BMM Pharma, Tablett 10 mg

The data, published in The Lancet today, demonstrated the estimated rate of TTS following a second dose of Vaxzevria was 2.3 per million vaccinees, comparable to the background rate observed in an unvaccinated population. It was 8.1 per million vaccinees after the first dose.1 The rate after the second dose is comparable to background rates observed in unvaccinated populations

Läs om Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose på Medicinkollen Nyheter.

In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population.....

Läs om Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people på Medicinkollen Nyheter.